glp 1 slow gastric emptying GLP-1 Medications – Community Education Gastrointestinal side effects of anti-obesity

Animal studies have linked it to a slowed progression of diabetes, obesity, and IBD

Plaintiffs allege that AstraZeneca failed to adequately warn patients and prescribing physicians about the potential risks, despite growing concerns within the medical community and clinical trial data suggesting dangers

Layne Norton, PhD, an expert in nutrition, fat loss, and metabolism

An increased risk was also supported by results of a large meta-analysis comprising a total of 36 double-blind randomized clinical trials with DPP-4 inhibitors with a total of 54,664 patients: there was a 58% increased risk of acute pancreatitis with DPP-4 inhibitors compared with other therapies (127)

The content is clear, effective, and supported